Xu Ya, Hou Yan-Yu, Wu Zheng, Fang Ze-Xuan, Wu Hua-Tao, Liu Jing
Department of Radiation Oncology, Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University, Shanwei 516600, Guangdong Province, China.
Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
World J Methodol. 2023 Sep 20;13(4):223-237. doi: 10.5662/wjm.v13.i4.223.
Ras suppressor 1 (RSU1), a highly conserved protein, plays an important role in actin cytoskeleton remodeling and cell-extracellular matrix adhesion. Aberration of RSU1 activity can cause changes in cell adhesion and migration, thereby enhancing tumor proliferation and metastasis. However, the correlation between RSU1 and gastrointestinal cancers (GICs), as well as its prognostic role related to tumor-infiltrating immune cells (TIICs) remains unclear.
To shows RSU1 plays a potential promoting role in facilitating tumor immune escape in GIC.
Differential expression of RSU1 in different tumors and their corresponding normal tissues was evaluated by exploring the Gene Expression Profiling Interactive Analysis (GEPIA) dataset. The correlation between RSU1 expression and prognosis of GIC cancer patients was evaluated by Kaplan-Meier plotter. Then, RSU1-correlated genes were screened and functionally characterized enrichment analysis. The correlation between RSU1 and TIICs was further characterized using the Tumor Immune Estimation Resource (TIMER). In addition, the correlation between RSU1 and immune cell surface molecules was also analyzed by TIMER.
High RSU1 expression was associated with poor overall survival of gastric cancer patients, exhibiting a hazard ratio (HR) = 1.36, first progression HR = 1.53, and post progression survival HR = 1.6. Specifically, high RSU1 Levels were associated with prognosis of gastric cancer in females, T4 and N3 stages, and Her-2-negative subtypes. Regarding immune-infiltrating cells, RSU1 expression level was positively correlated with infiltration of CD4+ T cells, macrophages, neutrophils, and dendritic cells (DCs) in colorectal adenocarcinoma and stomach adenocarcinoma. RSU1 expression was also predicted to be strongly correlated with immune marker sets in M2 macrophage, DCs and T cell exhaustion in GICs.
In gastrointestinal cancers, RSU1 is increased in tumor tissues, and predicts poor survival of patients. Increased RSU1 may be involved in promoting macrophage polarization, DC infiltration, and T cell exhaustion, inducing tumor immune escape and the development of tumors in GICs. We suggest that RSU1 is a promising prognostic biomarker reflecting immune infiltration level of GICs, as well as a potential therapeutic target for precision treatment through improving the immune response.
Ras抑制因子1(RSU1)是一种高度保守的蛋白质,在肌动蛋白细胞骨架重塑和细胞 - 细胞外基质黏附中起重要作用。RSU1活性异常可导致细胞黏附和迁移发生变化,从而增强肿瘤增殖和转移。然而,RSU1与胃肠道癌症(GIC)之间的相关性及其与肿瘤浸润免疫细胞(TIIC)相关的预后作用仍不清楚。
显示RSU1在促进GIC肿瘤免疫逃逸中发挥潜在的促进作用。
通过探索基因表达谱交互式分析(GEPIA)数据集评估RSU1在不同肿瘤及其相应正常组织中的差异表达。通过Kaplan-Meier绘图仪评估RSU1表达与GIC癌症患者预后的相关性。然后,筛选与RSU1相关的基因并进行功能特征富集分析。使用肿瘤免疫估计资源(TIMER)进一步表征RSU1与TIIC之间的相关性。此外,还通过TIMER分析了RSU1与免疫细胞表面分子之间的相关性。
RSU1高表达与胃癌患者较差的总生存率相关,风险比(HR)= 1.36,首次进展HR = 1.53,进展后生存HR = 1.6。具体而言,高RSU1水平与女性胃癌、T4和N3期以及Her-2阴性亚型的预后相关。关于免疫浸润细胞,RSU1表达水平与结肠腺癌和胃腺癌中CD4 + T细胞、巨噬细胞、中性粒细胞和树突状细胞(DC)的浸润呈正相关。RSU1表达也被预测与GIC中M2巨噬细胞、DC和T细胞耗竭中的免疫标志物集密切相关。
在胃肠道癌症中,肿瘤组织中RSU1增加,并预示患者生存不良。RSU1增加可能参与促进巨噬细胞极化、DC浸润和T细胞耗竭,诱导肿瘤免疫逃逸和GIC中肿瘤的发展。我们建议RSU1是一个有前景的预后生物标志物,反映GIC的免疫浸润水平,也是通过改善免疫反应进行精准治疗的潜在治疗靶点。